EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India

Anuradha Mehta iD, Debdeep Samaddar iD, Prabhat Bhargava iD, Anbarasan Sekar, George John iD, Revathy Krishnamurthy iD, Ayushi Sahay iD, Palak Popat iD, Purvi Haria iD, Rima Pathak iD, Shalaka Joshi iD, Tabassum Wadasadawala und 3 weitere

Indian Journal of Cancer · 2026

DOI: 10.4103/ijc.ijc_361_26 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Indian Journal of Cancer, 2026. Verfasst von Anuradha Mehta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hormone receptor-positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 − EBC patients treated at a tertiary cancer center in India.

Methods

This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 − EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan–Meier method.

Results

A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3–4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3–4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months.

Conclusion

In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 − EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAdultAgedFemaleHumansMiddle AgedAminopyridinesBenzimidazolesChemotherapy, AdjuvantIndiaPurinesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

AdjuvantCDK4/6 inhibitorhormone therapyreal-world outcome

Substanzen

abemaciclibAminopyridinesBenzimidazolesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsPurinesribociclib

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Training School Complex, Mumbai, Maharashtra, India.
  • Department of Radiation Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Pathology, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India.
  • Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India.

ORCID-Profile: Anuradha Mehta, Debdeep Samaddar, Prabhat Bhargava, George John, Revathy Krishnamurthy, Ayushi Sahay, Palak Popat, Purvi Haria, Rima Pathak, Shalaka Joshi, Rajiv Sarin, Sudeep Gupta, Sushmita Rath

Zitieren

APA

Mehta, A., Samaddar, D., Bhargava, P., Sekar, A., John, G., Krishnamurthy, R., Sahay, A., Popat, P., Haria, P., Pathak, R., Joshi, S., Wadasadawala, T., Sarin, R., Gupta, S., & Rath, S. (2026). Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_361_26

Vancouver

Mehta A, Samaddar D, Bhargava P, Sekar A, John G, Krishnamurthy R, et al. Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India. Indian Journal of Cancer. 2026. doi:10.4103/ijc.ijc_361_26

BibTeX
@article{Mehta2026,
  author = {Mehta, Anuradha and Samaddar, Debdeep and Bhargava, Prabhat and Sekar, Anbarasan and John, George and Krishnamurthy, Revathy and Sahay, Ayushi and Popat, Palak and Haria, Purvi and Pathak, Rima and Joshi, Shalaka and Wadasadawala, Tabassum and Sarin, Rajiv and Gupta, Sudeep and Rath, Sushmita},
  title = {Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India},
  journal = {Indian Journal of Cancer},
  year = {2026},
  doi = {10.4103/ijc.ijc_361_26}
}
Kostenlos starten →